Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Milestone Pharmaceuticals Inc
MIST | US
1.47
USD-0.02
-1.34%
MIST | US
About Milestone Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.47
Open
1.49
High
1.50
Low
1.43
Milestone Pharmaceuticals Inc. a biopharmaceutical company focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil a novel and potent calcium channel blocker which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal Canada.
View LessMIST | US
Risk
20.7
Sharpe
-0.73
Luna's Score
24/100
Recommendation
Sell
Luna says (MIST | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
24.8%1 month
20.7%3 months
34.0%6 months
38.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.48
Debt to equity
1.67
Debt to assets
0.60
Ent. to EBITDA
-1.43
Ent. to rev.
81.44
PEG
-
Other Fundamentals
EBITDA
-49.19M
MarketCap
78.31M
MarketCap(USD)
78.31M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-133.75
Short ratio
3.33
Short perc.
0.83
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.22
Range1M
0.22
Range3M
0.38
Volumes: Market Activity
Rel. volume
3.70
Price X volume
627.51K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.43 | - | Cheaper |
| Ent. to Revenue | 81.44 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.48 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 34.02 | - | Lower Risk |
| Debt to Equity | 1.67 | -1.23 | Expensive |
| Debt to Assets | 0.60 | 0.25 | Expensive |
| Market Cap | 78.31M | - | Emerging |
